GNBT Generex Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GNBT Generex

GNBT 0.00

Jan 27 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Doc Bones	2/13/2006 8:49:26 AM
	Read Replies (1) of 310

7:16AM Generex Biotech completes positive pre-IND meeting with FDA for its Avian Flu vaccine (GNBT) 1.41 : Co announces that on Feb 10, 2006, Antigen Express, its wholly owned immunotherapeutics subsidiary, concluded a positive Pre-Investigational New Drug Application meeting with the FDA regarding plans for the commencement of clinical trials of the proprietary and innovative Antigen Express vaccine to protect against the H5N1 avian influenza. As a consequence of the Pre-IND meeting, Antigen Express has clarified the development path (including clinical study design) and regulatory timetable for its innovative vaccine. Prior to the submission of its I.N.D, Antigen Express will conduct a toxicology study and a pre-clinical study to establish the vaccine's dosing regimen.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next